Add BrightSurf on Google Email

Ignore antifungal resistance in fungal disease at your peril, warn top scientists

The World Health Organisation accounts for around 3.8 million deaths annually from fungal pathogens that are either resistant or rapidly acquiring resistance to antifungal drugs. The narrow focus on bacteria will not combat antimicrobial resistance effectively, and the authors demand a broader discussion on fungal pathogens.

SourceUniversiteit van Amsterdam·JournalThe Lancet·TypeCommentary/editorial·DateSep 12, 2024

Gut bacteria influence responses to immunotherapy in patients with asbestos related cancer, Leicester study finds

A University of Leicester study has found that certain gut bacteria may influence whether a patient's immune system is successful in fighting mesothelioma, an aggressive form of cancer. Researchers suggest that dietary changes, such as increased fibre intake, could improve the benefits of immunotherapy for these patients.

SourceUniversity of Leicester·JournalNature Communications·TypeRandomized controlled/clinical trial·DateSep 5, 2024

Preliminary study shows potential of Manuka honey as a nutraceutical for breast cancer

A new study by UCLA investigators found that Manuka honey contains compounds that can help reduce tumor growth in preclinical models. The research suggests that Manuka honey could potentially be developed into a natural supplement or standalone treatment for ER-positive breast cancer, which accounts for most breast cancer cases.

USC study: Drug protects against air pollution-related Alzheimer’s signs in mice

A new USC study led by Caleb Finch shows how feeding mice the drug GSM-15606 provided protection against air pollution-related increases in proteins linked to Alzheimer's disease. The results indicate that GSM-15606 may one day have a role as a preventive measure against Alzheimer's in people living with air pollution.

SourceUniversity of Southern California·JournalAlzheimer s & Dementia·TypeExperimental study·DateAug 12, 2024

From fungi to pharmaceuticals: a milestone for the production of eutyscoparol A and violaceoid C

Researchers from Tokyo University of Science have developed an efficient method to synthesize eutyscoparol A and violaceoid C, two compounds with potential therapeutic properties. The new approach improves yields and simplifies synthesis steps, enabling further research into their pharmacological effects.

SourceTokyo University of Science·JournalAsian Journal of Organic Chemistry·TypeExperimental study·DateAug 9, 2024

Cutting-edge 3D-printed microneedle technology revolutionizes remote healthcare

This innovative system combines remote health monitoring and drug delivery using 3D-printed hollow microneedles, advancing personalized medicine. The integrated theranostic microneedle array measures key health indicators like pH, glucose, and lactate levels, while enabling rapid, pumpless, and point-of-care drug administration.

SourceTerasaki Institute for Biomedical Innovation·JournalAdvanced Healthcare Materials·TypeExperimental study·DateAug 7, 2024

Mechanism of hibernation found in ICU patients with contractile weakness of the diaphragm due to mechanical ventilation

ICU patients with contractile weakness of the diaphragm due to mechanical ventilation develop a state of hibernation, where myosin protein is trapped in an energy-saving state. This compromises diaphragm strength and independent breathing, leading to difficulties in weaning from the ventilator. Researchers have found a potential lead f...

SourceAmsterdam University Medical Center·JournalScience Translational Medicine·TypeObservational study·DateJul 31, 2024

Nature inspires a breakthrough: scientists develop revolutionary egg white-based bioink for advanced tissue engineering

Terasaki Institute scientists have created a novel bioink derived from egg whites, offering abundant proteins and excellent biocompatibility. This breakthrough technology has the potential to create more accurate tissue models for drug testing and develop functional tissue replacements for regenerative medicine applications.

SourceTerasaki Institute for Biomedical Innovation·JournalAdvanced Functional Materials·TypeExperimental study·DateJul 29, 2024

Recent insights and advances in treatment and management show promise in stemming the growing prevalence of diabetes

A recent paper surveys advances in diabetes pathogenesis and treatment, highlighting the role of genes, environmental factors, and social determinants. The study suggests that understanding these dynamics is key to developing targeted interventions to reduce diabetes risk and manage its complications.

SourceUniversity of California - Los Angeles Health Sciences·JournalCell·TypeLiterature review·DateJul 25, 2024

NYU Abu Dhabi researchers discover tumor suppressor protein Par-4 triggers unique cell death pathway in cancerous cells

Researchers at NYU Abu Dhabi have discovered that the tumor suppressor protein Par-4 can cause a unique type of cell death called ferroptosis in human glioblastoma cells, while sparing healthy cells. This new understanding has the potential to inform the development of novel treatments for various hard-to-treat cancers and neurodegener...

SourceNew York University·JournalCommunications Biology·DateJul 23, 2024

Combination treatment based on drug repurposing shows promise in the treatment of retinal degenerations

A combination treatment incorporating three drugs – tamsulosin, metoprolol, and bromocriptine – significantly slowed disease progression in four different animal models of IRD. The study suggests that drug repurposing could provide solutions for rare diseases like retinal degenerations, which are currently inaccessible therapeutically.

SourceUniversity of Eastern Finland·JournalNature Communications·DateJul 22, 2024

Novel drug application shows improved survival for patients with relapsed and refractory acute myeloid leukemia

A novel strategy using venetoclax and azacitidine demonstrates significant anti-cancer effect with mild toxicity for relapsed/refractory AML patients. The treatment showed markedly better survival rates after one year compared to a control group, with improved 'graft-versus-leukemia effects' via alterations of immune cells.

SourceOsaka Metropolitan University·JournalBlood Cancer Journal·TypeObservational study·DateJul 18, 2024

Targeting ABC transporters in PDAC – past, present, or future?

Researchers from Leiden University discuss targeting ABC transporters in pancreatic ductal carcinoma (PDAC), a cancer with poor survival rates. The authors highlight the potential of inhibiting ABC transporters to overcome chemoresistance and suggest developing stratification protocols to identify patients most likely to benefit.

SourceImpact Journals LLC·JournalOncotarget·TypeCommentary/editorial·DateJul 10, 2024

New AI approach optimizes antibody drugs

A new machine learning-based method uses 3D structure of protein backbone with large language models to predict molecular changes that lead to better antibody drugs. The approach resulted in a 25-fold improvement against a virus, outperforming traditional methods that rely on generating huge amounts of data about protein sequences.

SourceStanford University·JournalScience·DateJul 4, 2024

The molecular basis of how Pradimicin A binds to viral N-glycan, a potential SARS-CoV-2 entry inhibitor

Researchers discovered Pradimicin A's molecular basis for binding to viral N-glycan, showing promise as an anti-SARS-CoV-2 drug. The compound inhibits SARS-CoV-2 infectivity by interacting with branched oligomannose-containing glycans.

SourceInstitute for Glyco-core Research (iGCORE), Tokai National Higher Education and Research System·JournalBioorganic & Medicinal Chemistry·TypeExperimental study·DateJul 3, 2024

Targeted protein degradation: new adapter molecule expands therapeutic potential around the cell's waste disposal system

A new adapter molecule recruits a previously unknown E3 ligase for targeted protein degradation, expanding therapeutic options for cancer and rare diseases. The discovery offers advantages in development due to the molecule's smaller size and potential for tissue-specific application.

SourceCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences·JournalNature Communications·TypeExperimental study·DateJul 1, 2024

Nanorobot with hidden weapon kills cancer cells

Researchers at Karolinska Institutet developed nanorobots that target and kill cancer cells using a 'kill switch' activated in low pH environments. The study achieved a 70% reduction in tumour growth in mice, paving the way for further investigation into its potential as a cancer treatment.

SourceKarolinska Institutet·JournalNature Nanotechnology·TypeExperimental study·DateJul 1, 2024

Moffitt researchers develop synthesis method to enhance access to cancer-fighting withanolides

Researchers at Moffitt Cancer Center have developed a groundbreaking synthesis method for producing withanolides, a class of compounds that inhibit cancer cell growth and induce cell death. The scalable production of these compounds will advance cancer research and treatment development, offering new hope for patients.

SourceH. Lee Moffitt Cancer Center & Research Institute·JournalScience Advances·TypeExperimental study·DateJun 28, 2024

Global consensus for sarcopenia

A new global definition of sarcopenia is proposed, aiming to unify research and clinical practice. The definition may help identify low muscle mass or strength in older people, increasing the risk of poor outcomes such as fragility and disability.

SourceImpact Journals LLC·JournalAging-US·TypeCommentary/editorial·DateJun 26, 2024

Korea University identifies novel inhibitor HVH-2930 showing promise in overcoming trastuzumab resistance in HER2-positive breast cancer

A novel inhibitor HVH-2930 targeting heat shock protein 90 (HSP90) demonstrates efficacy against drug-resistant breast cancer cells. It selectively downregulates HER2 signaling, crucial for breast cancer progression, without triggering the heat shock response.

SourceKorea University College of Medicine·JournalTheranostics·TypeExperimental study·DateJun 25, 2024

New cellular models of myotonic dystrophy type 1 reflect the clinical diversity of the disease

Researchers have developed three new cellular models of myotonic dystrophy type 1 that accurately represent the clinical diversity of the disease. The models show great heterogeneity in genetic expansion and molecular alterations, making them suitable for studying pathophysiology and testing therapeutic options.

SourceGermans Trias i Pujol Research Institute·JournaliScience·TypeExperimental study·DateJun 20, 2024